Randomised, Multicenter Phase II Study in Patients With Metastatic Breast Cancer With Gemcitabine Plus Vinorelbine Versus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Capecitabine
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate
one year after last patient in
Volker Heinemann, PhD, MD
Principal Investigator
University of Munich - Klinikum Grosshadern
Germany: Federal Institute for Drugs and Medical Devices
Gemcitabin 02 MC
NCT00480597
October 2002
Name | Location |
---|